Diageo plc vs Edwards Lifesciences Corporation Common Stock — how do they compare? Diageo plc trades at $86.83 (market cap $47.67B), while Edwards Lifesciences Corporation Common Stock trades at $85.19 (market cap $48.56B). The key difference: Diageo plc and Edwards Lifesciences Corporation Common Stock are close in size by market cap, and Diageo plc pays a 2.3% dividend while Edwards Lifesciences Corporation Common Stock pays none. Which is the better fit depends on your goals.
| DEO | EW | |
|---|---|---|
Market Cap | $47.67B | $48.56B |
Volume | 893,372 | 6,520,488 |
Sector | Consumer Staples | Health |
52-Week High | $102.14 | $95.18 |
52-Week Low | $72.47 | $72.65 |
Typical Hold Time | 66 Days | — |
Enterprise Value | $68.09B | $45.01B |
Dividend Yield | 2.3% | — |
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $86.73, up 2.36% with bullish technical indicators and strong analyst support. The company demonstrates solid fundamentals with consistent earnings beats, a 15.82% ROE, and positive cash flow generation. Recent corporate developments include a new CFO appointment and marketing initiatives across key brands, though revenue declined to $19.6B in 2026 with margin compression.
The stock presents a compelling turnaround opportunity with analyst consensus favoring bullish sentiment (48.65% buy ratings). Key catalysts include cost-saving initiatives and brand revitalization, while risks involve US market challenges, regulatory scrutiny in India, and ongoing margin pressure. The current valuation at 27.91 P/E appears reasonable given the growth potential.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →